Search

Displaying results 761 - 770 of 8517 in total
  1. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including

  2. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

  3. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions.

  4. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective … Sofosbuvir is also available as a fixed dose combination product with [DB11613] as the commercially available product Epclusa.

  5. Drug

    Hydrochlorothiazide

    go.drugbank.com/drugs/DB00999
    ApprovedInvestigationalVet approved

    [L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.[L8444]

    Mixtures: RAMIPRIL COMP BAS 5/25MG, RAMIPRIL COMP BAS 5/25MG
  6. Drug

    Lemon

    go.drugbank.com/drugs/DB10538
    Approved

    Lemon allergenic extract is used in allergenic testing.

    Mixtures: Tea Bags
  7. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    The final purified concentrate contains albumin as a stabilizer.[L1053]. The complex was developed by CSL Behring or Baxter Healthcare Corporation and approved in the 90s. … Bleeding can range in severity from minor concerns, such as nosebleeds, to more serious events such as hemorrhaging in the joints, brain, or digestive tract [A32280].

  8. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … [L44508] The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.[L47486]

  9. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … More recently, it has also been approved for the treatment of giant cell arteritis in adults and active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.[L10896]

  10. Drug

    Asunaprevir

    go.drugbank.com/drugs/DB11586
    ApprovedWithdrawn

    Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]